AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

FUJIFILM Irvine Scientific Launches BalanCD Gal Supplement for biotherapeutic development

September 10, 2019

SANTA ANA, Calif.--(BUSINESS WIRE)--Sep 10, 2019--

FUJIFILM Irvine Scientific, Inc., a world leader in the optimization, development and manufacture of cell culture media and industrial cell culture solutions, today introduced BalanCD Gal Supplement. The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve desired glycan profiles for improved product quality and antibody efficacy.

Glycosylation is a critical aspect in development and optimization of protein-based therapeutics. The type and level of glycosylation can significantly affect antibody binding, function, and therapeutic efficacy. Galactosylation (the glycosylation of galactose) is a key method for controlling product quality due to the significant impact it has on antibody function, and the ability to control levels of galactosylation through the cell culture medium.

BalanCD Gal Supplement is a chemically-defined, animal component-free formula designed to increase N -linked galactosylation with a scalable protocol, offering researchers a simple method to control the process through the cell culture medium. The supplement is effective at low concentrations and is compatible with any basal growth medium.

BalanCD Gal Supplement has been developed as part of the BalanCD CHO media platform - an extended portfolio of chemically-defined, animal component-free growth and feed media formulated using Rational Culture Media Design. This multidimensional approach uses sequential, complementary development methods to leverage FUJIFILM Irvine Scientific scientists’ expertise in the effects of components and process parameters. The result is a media platform that delivers the precise combination of nutrients to maximize productivity, growth, and viability of CHO cell lines.

“The BalanCD Gal Supplement has been designed to incorporate seamlessly into our BalanCD media portfolio, providing researchers in biotherapeutic development with a holistic, efficient growth and production platform. Developed by our expert research and development group, the new supplement supports scientists in streamlining workflows, ultimately to advance emerging therapies,”said Robert Newman PhD, Chief Scientific Officer, FUJIFILM Irvine Scientific.

For more information visit http://www.irvinesci.com/industrial-cell-culture.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190910005481/en/

CONTACT: Lorna Cuddon

Zyme Communications

Phone: +44 (0)7811996942

Email:lorna.cuddon@zymecommunications.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: Irvine Scientific

Copyright Business Wire 2019.

PUB: 09/10/2019 05:37 AM/DISC: 09/10/2019 05:37 AM

http://www.businesswire.com/news/home/20190910005481/en

All contents © copyright 2019 The Associated Press. All rights reserved.